| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Osteosarcoma | D012516 | 50 associated lipids |
| Glioma | D005910 | 112 associated lipids |
(e,z)-farnesol
(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol
PubChem Biomolecular Interactions and Pathways
All references with (e,z)-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Lin HP et al. | Localization of isoprenylated antigen of hepatitis delta virus by anti-farnesyl antibodies. | 1999 | J. Gen. Virol. | pmid:9934689 |
| Weissmann N et al. | Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. | 1999 | Am. J. Physiol. | pmid:9887060 |
| Niv H et al. | Membrane interactions of a constitutively active GFP-Ki-Ras 4B and their role in signaling. Evidence from lateral mobility studies. | 1999 | J. Biol. Chem. | pmid:9880539 |
| Fisher JE et al. | Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. | 1999 | Proc. Natl. Acad. Sci. U.S.A. | pmid:9874784 |
| Shipman CM et al. | The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. | 1998 | Cancer Res. | pmid:9850051 |
| Strickland CL et al. | Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. | 1998 | Biochemistry | pmid:9843427 |
| Laezza C et al. | v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway. | 1998 | Proc. Natl. Acad. Sci. U.S.A. | pmid:9811854 |
| Ferdinandy P et al. | Rapid pacing-induced preconditioning is recaptured by farnesol treatment in hearts of cholesterol-fed rats: role of polyprenyl derivatives and nitric oxide. | 1998 | Mol. Cell. Biochem. | pmid:9774182 |
| Pei ZM et al. | Role of farnesyltransferase in ABA regulation of guard cell anion channels and plant water loss. | 1998 | Science | pmid:9765153 |
| Miquel K et al. | Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. | 1998 | J. Biol. Chem. | pmid:9748300 |